bioAffinity Technologies Announces Acceptance of Australian Patent Application

On October 28, 2025, bioAffinity Technologies, Inc. announced that the Australian Patent Office has accepted its patent application AU 2019253111 titled 'System and Method for Determining Lung Health.' This patent covers methods using flow cytometry combined with fluorescent probes to detect cellular and molecular signatures of multiple lung diseases. The acceptance of this patent strengthens bioAffinity's global patent portfolio and underscores the potential of its technology to improve the diagnosis and management of lung diseases. The company's flagship product, CyPath® Lung, remains central to its commercial efforts, providing a noninvasive tool for assessing lung nodules detected by low-dose CT scans. The Australian patent complements existing intellectual property protections in the U.S. and other jurisdictions, safeguarding the core technology behind CyPath® Lung and other diagnostics in the pipeline.